Table 2.
Prevalence of symptoms and signs among VCM-exposed workers stratified by VCM exposure
| Symptoms and signs |
VCM exposure |
|||||
| ≤ 15 000 mg | > 15 000 mg | Total | ||||
| (n = 186) | (n = 52) | (n = 238) | ||||
| Neurastheniaa | 26 | 14.00% | 14 | 26.92% | 40 | 16.81% |
| Respiratory system | 3 | 1.60% | 1 | 1.92% | 4 | 1.68% |
| Digestive system | 4 | 2.15% | 1 | 1.92% | 5 | 2.10% |
| Pharyngitisa | 104 | 55.90% | 34 | 65.38% | 138 | 57.98% |
| ECG | 19 | 10.20% | 5 | 9.61% | 24 | 10.08% |
| Nephridium USG | 1 | 0.53% | 2 | 3.85% | 3 | 1.26% |
| Gall bladder USG | 4 | 2.15% | 4 | 7.69% | 8 | 3.36% |
| Liver USGa | 34 | 18.30% | 17 | 32.69% | 51 | 21.43% |
| Fatty liver | 7 | 3.76% | 3 | 5.77% | 10 | 4.20% |
| Hepatic hemangioma | 1 | 0.53% | 2 | 3.85% | 3 | 1.26% |
| Splenomegaly | 8 | 4.30% | 2 | 3.85% | 10 | 7.08% |
aP < 0.05 vs ≤ 15 000 mg group.